GlassScriptPhysician profile
Moe Zan
NPI 1831365378
$24,829.66
in general payments reported to CMS, 2019-2025
53 companies · $4,606 in 2025
The $4,606 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,702 · 2020: $2,770 · 2021: $2,727 · 2022: $3,545 · 2023: $3,772 · 2024: $3,708 · 2025: $4,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,792.51 |
| Education | $293.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,719.58 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,853.13 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,378.35 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,118.96 | 2019-2025 | |
| Ucb, INC. | $1,722.66 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,721.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $814.41 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $741.92 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $704.78 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $669.35 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $588.90 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $588.14 | 2022-2025 | Lupkynis |
| Radius Health, INC. | $586.92 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $580.47 | 2019-2025 | Orencia |
| Genentech USA, INC. | $493.89 | 2019-2025 | Actemra, Rituxan, Gazyva |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moe Zan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.